Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Plain-language summary

This study looks at different targeted treatment strategies (Osimertinib, Alectinib, Crizotinib, Savolitinib, and chemotherapy) in patients with advanced non-small cell lung cancer that carries oncogenic gene mutations such as EGFR, ALK, or ROS1. To join, patients must be 18 or older with confirmed mutations and Stage IV disease. The study is being conducted in Phase 2 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Recruiting

Sponsor

Hunan Province Tumor Hospital

Intervention

Osimertinib, Alectinib 150 MG, Crizotinib 250 MG, Savolitinib, Crizotinib., Chemotherapy

Start date

4/16/2020

Estimated completion

12/24/2027

Countries

China

Related genes

Locations

• Changsha, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
2. Age ≥ 18 years.
3. Histologically or cytologically confirmed, Stage IV NSCLC.
4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
5. ECOG 0-1.
6. Predicted survival ≥ 12 weeks.
7. Adequate bone marrow hematopoiesis and organ function
8. Presence of measurable lesions according to RECIST 1.1.

Exclusion Criteria:

The patient did not match from the Inclusion Criteria.